Our Obligations to the Poor
The relationship between the rich and the poor countries of the world has been questioned in a number of ways today. Oxfam have released a report, Investing for Life, which suggests that pharmaceutical companies are missing an important opportunity by not focussing their attention on the large health problems of the poorest countries. At the same time, in the US, apparently significant developments have been made in the production of drought–resistant crops and, in the UK, the government’s chief scientific adviser will call for a rethink on GM crops.
These two issues pull in interestingly different ways. In the first case, the challenging question is how best to balance the value of a market-based research industry with the need to provide assistance to the poorest countries. In the second, the challenge is the price we are prepared to pay for our worries about genetically modified crops. In both cases our obligations to the poor sheds important light on the values of our society.